Anti-obesity drugs: What does sibutramine offer? An analysis of its potential contribution to obesity treatment

Experimental and Clinical Endocrinology and Diabetes

Volumn 106, Issue SUPPL. 2, 1998, Pages 35-40

  Van Gaal, L F ^a   Wauters, M A ^a   De Leeuw, I H ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Obesity; Pharmacotherapy; Sibutramine

Indexed keywords

AMINE; DEXFENFLURAMINE; GLUCOSE; LIPID; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE; URIC ACID;

ANOREXIA; ANXIETY; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DEPRESSION; DOSE RESPONSE; DRUG ABSORPTION; DRUG METABOLISM; DYSMENORRHEA; ENERGY EXPENDITURE; FIRST PASS EFFECT; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; LIPID BLOOD LEVEL; NAUSEA; NERVOUSNESS; OBESITY; ORAL DRUG ADMINISTRATION; PARESTHESIA; PRIORITY JOURNAL; RECTUM DISEASE; SATIETY; SIDE EFFECT; SUBCUTANEOUS FAT; TACHYCARDIA; URIC ACID BLOOD LEVEL; VERTIGO; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0031710888     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1212035     Document Type: Conference Paper

References (22)

1. Bray GA, Ryan DH et al.: A double blind randomized placebo-controlled trial of sibutramine: a new weight loss medication. Obesity Res 4: 263-270, 1996
2. Buckett WR, Thomas PC, Luscombe GP: The pharmacology of sibutramine hydrocholoride, a new antidepressant which induces rapid noradrenergic down-regulation. Prog Neuropsychopharmacol Biol Psychiatry 12. 575-584, 1988
3. 3H]5-HT uptake: effect of administration of various antidepressant treatments. Neuropharmacology 32: 737-743, 1993
4. Després JP: Abdominal obesity as an important component of the insulin resistance syndrome. Nutrition 9: 452-459, 1993
5. Drouin P, Hanotin C, Thomas F, Leutenegger E: Efficacy and tolerability of sibutramine vs dexfenfluramine in obese subjects. Int J Obesity 19 (suppl 2): 144, 1995
6. Folsom AR, Qamhieh HT, Wing RR, Jeffery RW, Stinson VL, Kuller LH, Wu KK: Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other haemostatic factors in moderately overweight adults. Arterioscler Thromb Vasc Biol 13: 162-169, 1993
7. Goldstein DJ: Beneficial health effects of modest weight loss. Int J Obesity 16: 397-415, 1991
8. Griffiths J, Byrnes AE, Frost G, Bloom SR, Finer N, Jones SP, Romance FM: Sibutramine in the treatment of overweight non-insulin-dependent diabetics. Int J Obesity 19 (suppl 2): 41, 1995
9. Guy-Grand B: Pharmacological approaches to intervention. Int J Obesity 21 (suppl 1): S22-S24, 1997
10. Guy-Grand B, Apfelbaum M, Gerpaldi G, Gries A, Lefèbvre P, Turner P: International trial of long-term dexfenfluramine in obesity. Lancet 2: 1142-1145, 1989
11. Hughes TA, Gwynne JT, Switzer BR, Herbst C, White G: Effects of caloric restriction and weight loss on glycemic control, insulin release and resistance, and atherosclerostic risk in obese patients with type II diabetes. Am J Med 77: 7-17, 1984
12. Jones SP, Smith IG, Kelly F, Gray JA: Long-term weight loss with sibutramine. Int J Obesity 19 (suppl 2): 41, 1995
13. Jung RT, Manning RM, Leese GP, Newton RW: The comparison of four weight reducing strategies aimed at overweight diabetic patients. Diabet Med 12: 409-415, 1995
14. Kelly F, Wade AG, Jones SP, Johnson SG: Sibutramine hydrochloride vs dexfenfluramine: weight loss in obese subjects. Int J Obesity 18 (suppl 2): 61, 1994
15. Lean MEJ: Sibutramine - a review of clinical efficacy. Int J Obesity 21 (suppl 1): 30-36, 1997
16. Liu YL, Kashani SM, Heal DJ, Stock MJ: Effect of sibutramine on tissue glucose utilization in the rat. Br J Pharmacol 117: P324, 1996
17. Marks SJ, Moore NR, Clark ML, Hockaday T: Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM. Obesity Res 4: 1-7, 1996
18. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obesity 21 (suppl 1): 25-29, 1997
19. Takahashi S, Yamamoto T, Tsutsumi Z, Moriwaki Y, Yamakita J, Higashino K: Close correlation between visceral fat accumulation and uric acid metabolism in healthy men. Metabolism 1997; 46: 1162-1165
20. Van Gaal L, Rillaerts E, Greten W, De Leeuw I: Relationship of body fat distribution pattern to atherogenic risk factors in non-insulin dependent diabetes. Preliminary results. Diabetes Care 11: 103-106, 1988
21. Van Gaal LF, Wauters MA, De Leeuw IH: The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obesity 21 (suppl 1): S5-S9, 1997
22. Wing RR, Blair EH, Bononi P, Marcus MD, Watanabe R, Bergman RN: Caloric restriction per se is a significant factor in improvements in glycaemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care 17: 30-36, 1994